Clinicopathological characteristics and prognosis of 232 patients with poorly differentiated gastric neuroendocrine neoplasms

Table 1 Clinicopathological characteristics of 232 patients with gastric neuroendocrine carcinoma and univariate analysis

Classification	n	Median survival time/mo	P value
Age (yr)			0.26
< 60	80	12.56 (9.42-14.57)
≥ 60	152	14.85 (11.80-18.11)
Gender			0.32
Male	191	14.50 (11.78-16.21)
Female	41	11.50 (7.94-12.05)
Tumor number			0.01
Solitary	5	14.02 (11.93-16.06)
Multiple	214	5.98 (3.40-6.60)
NR	13	NR	NR
Tumor diameter (cm)			0.01
0-5	105	18.10 (9.35-20.64)
> 5	99	11.50 (9.41-16.58)
NR	28	NR	NR
Invasion			0.02
M1/S/MP2	82	16.27 (12.51-17.49)
Serosa	116	11.54 (7.54-14.54)
NR	34	NR	NR
Tumor site			0.09
Cardia	65	16.12 (11.53-18.46)
Fundus	15	19.88 (3.99-28.00)
Body	33	15.98 (9.46-20.53)
Antrum	27	11.80 (8.73-17.26)
C + F	35	12.50 (7.96-16.03)
Other	40	15.23 (8.59-23.40)
NR	17	NR	NR
Pathological type			0.68
Large cell NEC	41	12.96 (12.11-13.84)
Small cell NEC	26	16.33 (11.30-20.69)
MANEC	38	12.33 (8.80-15.19)
NR	127	14.31 (10.40-17.59)
Ki-67 index			0.61
20%-50%	60	12.69 (7.50-16.49)
50%-70%	114	14.10 (11.74-16.25)
> 70%	38	13.23 (0.00-26.80)
NR	20	NR	NR
Endoscopic performance			0.90
Polypoid	7	15.00 (11.85-16.14)
Mucosal elevation	28	17.19 (6.99-25.00)
Ulcer	157	13.69 (10.66-15.33)
Other	40	11.00 (9.09-10.90)
Tumor N staging			0.16
N0	50	20.00 (5.30-30.70)
N1-N3	174	13.11 (9.95-16.00)
NR	8	NR	NR
Distant metastasis			< 0.001
No	157	17.43 (12.94-21.05)
Yes	73	11.64 (9.04-12.95)
NR	2	NR	NR
AJCC stage			< 0.001
I	5	88.26 (36.06-139.94)
II	25	31.34 (13.56-48.43)
III	113	16.12 (13.43-18.56)
IV	86	11.52 (9.05-12.94)
NR	3	NR	NR
Treatment			0.01
Surgery	86	15.47 (10.87-19.12)
Chemotherapy	40	12.10 (10.24-13.75)
Surgery + chemotherapy	92	15.70 (9.99-20.00)
Other	14	11.00 (0.00-21.68)

NR: Not reported.

M¹: Mucosa; S: Submucosa.

MP²: Muscularis propria.

C + F: Cardia + Fundus; NEC: Neuroendocrine carcinoma; MANEC: Mixed adenoneuroendocrine carcinoma; AJCC: American Joint Committee on Cancer.